Abstract
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / radiotherapy
-
Colorectal Neoplasms / surgery
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / radiotherapy
-
Kidney Neoplasms / surgery
-
Lactones / therapeutic use
-
Macrolides
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / radiotherapy
-
Ovarian Neoplasms / surgery
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Phytogenic
-
Lactones
-
Macrolides
-
rhizoxin